Clinical characteristics of ITP patients receiving decitabine treatment
| Patients . | Age, y . | Sex . | Platelet count, ×109/L . | Antiplatelet antibodies . | Major previous drugs . | |
|---|---|---|---|---|---|---|
| Anti-GPIIb/IIIa . | Anti-GPIb/IX . | |||||
| 1 | 21 | M | 3 | − | − | DXM, Pred, rhTPO, TPO-RA |
| 2 | 46 | F | 19 | + | − | DXM, rhTPO, CA, |
| 3 | 51 | M | 25 | − | − | DXM, Pred, |
| 4 | 60 | M | 9 | − | + | DXM, Pred, RTX, SP |
| 5 | 26 | F | 13 | − | − | DXM, IVIG, rhTPO |
| 6 | 70 | F | 14 | − | − | DXM, Pred, IVIG, rhTPO |
| 7 | 34 | M | 6 | + | + | DXM, Pred, RTX |
| 8 | 42 | F | 28 | − | − | DXM, rhTPO |
| 9 | 31 | F | 11 | − | − | DXM, Pred, CA |
| 10 | 65 | M | 20 | − | + | DXM, Pred, rhTPO, Danazol |
| 11 | 48 | F | 12 | − | − | DXM, rhTPO, CA |
| 12 | 18 | M | 14 | − | − | Pred, rhTPO, CsA |
| 13 | 45 | F | 16 | − | − | DXM, IVIG, RTX |
| Patients . | Age, y . | Sex . | Platelet count, ×109/L . | Antiplatelet antibodies . | Major previous drugs . | |
|---|---|---|---|---|---|---|
| Anti-GPIIb/IIIa . | Anti-GPIb/IX . | |||||
| 1 | 21 | M | 3 | − | − | DXM, Pred, rhTPO, TPO-RA |
| 2 | 46 | F | 19 | + | − | DXM, rhTPO, CA, |
| 3 | 51 | M | 25 | − | − | DXM, Pred, |
| 4 | 60 | M | 9 | − | + | DXM, Pred, RTX, SP |
| 5 | 26 | F | 13 | − | − | DXM, IVIG, rhTPO |
| 6 | 70 | F | 14 | − | − | DXM, Pred, IVIG, rhTPO |
| 7 | 34 | M | 6 | + | + | DXM, Pred, RTX |
| 8 | 42 | F | 28 | − | − | DXM, rhTPO |
| 9 | 31 | F | 11 | − | − | DXM, Pred, CA |
| 10 | 65 | M | 20 | − | + | DXM, Pred, rhTPO, Danazol |
| 11 | 48 | F | 12 | − | − | DXM, rhTPO, CA |
| 12 | 18 | M | 14 | − | − | Pred, rhTPO, CsA |
| 13 | 45 | F | 16 | − | − | DXM, IVIG, RTX |
CA, caffeic acid; CsA, cyclosporine A; IVIg, intravenous gamma globulin; Pred, prednisone; rhTPO, recombinant human thrombopoietin; RTX, rituximab; SP, splenectomy, danazol; TPO-RA, thrombopoietin receptor agonist.